GW Expands Cannabinoid Research In The Field Of Diabetes And Metabolic Disease
GW Expands Cannabinoid Research In The Field Of Diabetes And Metabolic Disease
"GW Metabolic Research Laboratory" established in conjunction with Professor Cawthorne and the Clore Laboratory, University of Buckingham Porton Down, UK, 16 June 2009: GW Pharmaceuticals plc (GWP:AIM) announces that it has entered into an exclusive strategic alliance with Professor Mike Cawthorne and the Clore Laboratory, University of Buckingham, focusing on the research of cannabinoids, and other phytomedicines, in the field of type 2 diabetes and metabolic disease.